Myriad Genetics (MYGN) Tops Q3 EPS by 4c, Raises Guidance

Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of $0.27, $0.04 better than the analyst estimate of $0.23. Revenue for the quarter came in at $196.9 million versus the consensus estimate of $189.1 million.

GUIDANCE:

Myriad Genetics sees Q4 2017 EPS of $0.26-$0.28. Myriad Genetics sees Q4 2017 revenue of $192-194 million.

Myriad Genetics sees FY 2017 EPS of $1.01-$1.03 Myriad Genetics sees FY 2017 revenue of $763-765 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c